Evidence for rifampicin-promoted readthrough of a fully rho-dependent transcriptional terminator.
We have previously presented evidence that rifampicin promotes readthrough of various transcriptional terminators in vivo. This conclusion was based on measurements of galactokinase or beta-galactosidase synthesis in Escherichia coli strains, harbouring plasmids having the terminators fused upstream of galK or lacZ respectively. The terminators tested did not include any known example of a fully rho-dependent signal. We now show that the drug does stimulate galactokinase production when galK is fused downstream of such a terminator: the first rightward terminator of lambda. We also show that the nusA1 host mutation affects neither termination nor the drug response at this site.
D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics*; D005686:Galactokinase / Q000235:genetics*; D005696:Galactosidases / Q000235:genetics*; D009154:Mutation; D010641:Phenotype; D010957:Plasmids; D012234:Rho Factor / Q000235:genetics*; D012293:Rifampin / Q000494:pharmacology*; D014157:Transcription Factors / Q000235:genetics*; D014158:Transcription, Genetic / Q000187:drug effects*; D001616:beta-Galactosidase / Q000235:genetics*
D012234:Rho Factor; D014157:Transcription Factors; D005686:Galactokinase; D005696:Galactosidases; D001616:beta-Galactosidase; D012293:Rifampin